Literature DB >> 32342598

B cell-derived IL-1β and IL-6 drive T cell reconstitution following lymphoablation.

Suheyla Hasgur1, Ran Fan1, Daniel B Zwick1, Robert L Fairchild1, Anna Valujskikh1.   

Abstract

Understanding the mechanisms of T cell homeostatic expansion is crucial for clinical applications of lymphoablative therapies. We previously established that T cell recovery in mouse heart allograft recipients treated with anti-thymocyte globulin (mATG) critically depends on B cells and is mediated by B cell-derived soluble factors. B cell production of interleukin (IL)-1β and IL-6 is markedly upregulated after heart allotransplantation and lymphoablation. Neutralizing IL-1β or IL-6 with mAb or the use of recipients lacking mature IL-1β, IL-6, IL-1R, MyD88, or IL-6R impair CD4+ and CD8+ T cell recovery and significantly enhance the graft-prolonging efficacy of lymphoablation. Adoptive co-transfer experiments demonstrate a direct effect of IL-6 but not IL-1β on T lymphocytes. Furthermore, B cells incapable of IL-1β or IL-6 production have diminished capacity to mediate T cell reconstitution and initiate heart allograft rejection upon adoptive transfer into mATG treated B cell deficient recipients. These findings reveal the essential role of B cell-derived IL-1β and IL-6 during homeostatic T cell expansion in a clinically relevant model of lymphoablation.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  B cell biology; T cell biology; basic (laboratory) research/science; cytokines/cytokine receptors; immunobiology; immunosuppression/immune modulation; lymphocyte biology

Mesh:

Substances:

Year:  2020        PMID: 32342598      PMCID: PMC7956246          DOI: 10.1111/ajt.15960

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  60 in total

1.  TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor signal adaptor protein.

Authors:  Bethany M Tesar; Jiasheng Zhang; Qi Li; Daniel R Goldstein
Journal:  Am J Transplant       Date:  2004-09       Impact factor: 8.086

Review 2.  Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.

Authors:  S Samuel Weigt; Vyacheslav Palchevskiy; John A Belperio
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

3.  In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy.

Authors:  Yifa Chen; Peter S Heeger; Anna Valujskikh
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

4.  IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.

Authors:  Shlomo Z Ben-Sasson; Jane Hu-Li; Juan Quiel; Stephane Cauchetaux; Maya Ratner; Ilana Shapira; Charles A Dinarello; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

5.  ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury.

Authors:  Naoko Kamo; Bibo Ke; Amir A Ghaffari; Xiu-da Shen; Ronald W Busuttil; Genhong Cheng; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

6.  Protective effect of T cell depletion in murine renal ischemia-reperfusion injury.

Authors:  Naoko Yokota; Frank Daniels; John Crosson; Hamid Rabb
Journal:  Transplantation       Date:  2002-09-27       Impact factor: 4.939

Review 7.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

8.  IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells.

Authors:  Masaki Tajima; Daiko Wakita; Daisuke Noguchi; Kenji Chamoto; Zhang Yue; Kazunori Fugo; Harumichi Ishigame; Yoichiro Iwakura; Hidemitsu Kitamura; Takashi Nishimura
Journal:  J Exp Med       Date:  2008-04-21       Impact factor: 14.307

Review 9.  New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity.

Authors:  Mohamad Mohty; Andrea Bacigalupo; Faouzi Saliba; Andreas Zuckermann; Emmanuel Morelon; Yvon Lebranchu
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

10.  Identification of IFN-γ-producing innate B cells.

Authors:  Yan Bao; Xingguang Liu; Chaofeng Han; Sheng Xu; Bin Xie; Qian Zhang; Yan Gu; Jin Hou; Li Qian; Cheng Qian; Huanxing Han; Xuetao Cao
Journal:  Cell Res       Date:  2013-12-03       Impact factor: 25.617

View more
  2 in total

1.  Macrophage-inducible C-type lectin activates B cells to promote T cell reconstitution in heart allograft recipients.

Authors:  Suheyla Hasgur; Yosuke Yamamoto; Ran Fan; Michael Nicosia; Victoria Gorbacheva; Daniel Zwick; Motoo Araki; Robert L Fairchild; Anna Valujskikh
Journal:  Am J Transplant       Date:  2022-04-01       Impact factor: 9.369

2.  Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus.

Authors:  Hao Cheng; Xiao-Ying Zhang; Hui-Dan Yang; Zhen Yu; Cheng-Lan Yan; Chong Gao; Hong-Yan Wen
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.